This is a Validated Antibody Database (VAD) review about chimpanzee LOC450151, based on 34 published articles (read how Labome selects the articles), using LOC450151 antibody in all methods. It is aimed to help Labome visitors find the most suited LOC450151 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
BioLegend
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 3
BioLegend LOC450151 antibody (BioLegend, 311410) was used in flow cytometry on human samples (fig 3). J Virol (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig s1
BioLegend LOC450151 antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig s1). JCI Insight (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 2l
BioLegend LOC450151 antibody (BioLegend, 311426) was used in flow cytometry on human samples (fig 2l). Cancer Res (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:50; fig 2a
BioLegend LOC450151 antibody (BioLegend, W6/32) was used in flow cytometry on human samples at 1:50 (fig 2a). Nat Immunol (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 5b
BioLegend LOC450151 antibody (BioLegend, w6/32) was used in flow cytometry on human samples (fig 5b). J Virol (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig s1b
BioLegend LOC450151 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig s1b). Nature (2017) ncbi
mouse monoclonal (W6/32)
  • blocking or activating experiments; human; loading ...
BioLegend LOC450151 antibody (BioLegend, w6/32) was used in blocking or activating experiments on human samples . J Immunol (2017) ncbi
mouse monoclonal (W6/32)
  • immunocytochemistry; human; 1:500; loading ...; fig 1a
BioLegend LOC450151 antibody (BioLegend, W6/32) was used in immunocytochemistry on human samples at 1:500 (fig 1a). J Cell Sci (2017) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig e6a
In order to report preclinical studies using a CRISPR-based methodology to target hematopoietic stem cells to treat beta-haemoglobinopathies, BioLegend LOC450151 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig e6a). Nature (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 3e, 3f
BioLegend LOC450151 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig 3e, 3f). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...
BioLegend LOC450151 antibody (BioLegend, W6/32) was used in flow cytometry on human samples . J Exp Med (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 1a
In order to assess the effects of platelet-derived ectosomes on natural killer cells, BioLegend LOC450151 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig 1a). J Immunol (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig s2
In order to determine modulation of presentation of cell surfaced calreticulin by alpha-integrin function and expression, BioLegend LOC450151 antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig s2). Cell Death Dis (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 3c
BioLegend LOC450151 antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig 3c). J Immunol (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; tbl 1
BioLegend LOC450151 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (tbl 1). J Immunol (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig s6b
In order to test if AML patients treated decitabine have induced expression of cancer testis antigens, BioLegend LOC450151 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig s6b). Oncotarget (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:100; fig 2
BioLegend LOC450151 antibody (Biolegend, W6/32) was used in flow cytometry on human samples at 1:100 (fig 2). Nat Commun (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 5
BioLegend LOC450151 antibody (Biolegend, 311404) was used in flow cytometry on human samples (fig 5). Br J Cancer (2015) ncbi
mouse monoclonal (W6/32)
  • immunohistochemistry; human; 1:50
In order to investigate the dynamics and characteristics of natural killer cell types in the human ocular mucosal surface in situ during infection with group D human adenoviruses, BioLegend LOC450151 antibody (Biolegend, W6/32) was used in immunohistochemistry on human samples at 1:50. Mucosal Immunol (2016) ncbi
mouse monoclonal (W6/32)
  • other; human; fig 2
In order to characterize capabilities and potentials of extracellular vesicle (EV) array, BioLegend LOC450151 antibody (BioLegend, 311402) was used in other on human samples (fig 2). J Extracell Vesicles (2015) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; tbl 1
BioLegend LOC450151 antibody (Biolegend, W.6.32) was used in flow cytometry on human samples (tbl 1). Cancer Immunol Immunother (2015) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 1
  • immunocytochemistry; human; fig 3
BioLegend LOC450151 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig 1) and in immunocytochemistry on human samples (fig 3). Cancer Immunol Res (2015) ncbi
mouse monoclonal (W6/32)
  • ELISA; human; fig s1
BioLegend LOC450151 antibody (Biolegend, 311402) was used in ELISA on human samples (fig s1). MAbs (2015) ncbi
mouse monoclonal (W6/32)
  • blocking or activating experiments; human; 15 ug/ml; fig 4
BioLegend LOC450151 antibody (BioLegend, W6/32) was used in blocking or activating experiments on human samples at 15 ug/ml (fig 4). Vaccine (2015) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 1
BioLegend LOC450151 antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig 1). J Infect Dis (2015) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human
BioLegend LOC450151 antibody (BioLegend, W6/32) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human
BioLegend LOC450151 antibody (BioLegend, W6/32) was used in flow cytometry on human samples . J Leukoc Biol (2014) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human
BioLegend LOC450151 antibody (BioLegend, w6/32) was used in flow cytometry on human samples . J Immunol (2014) ncbi
mouse monoclonal (W6/32)
  • immunohistochemistry; mouse; 1:50; fig 3
BioLegend LOC450151 antibody (BioLegend, 311402) was used in immunohistochemistry on mouse samples at 1:50 (fig 3). Mol Cancer Res (2015) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human
BioLegend LOC450151 antibody (Biolegend, W6/32) was used in flow cytometry on human samples . Immunology (2014) ncbi
mouse monoclonal (W6/32)
  • immunocytochemistry; human; 1:50
BioLegend LOC450151 antibody (Biolegend, W6/32) was used in immunocytochemistry on human samples at 1:50. Mol Ther (2014) ncbi
mouse monoclonal (W6/32)
  • western blot; human; fig 2
In order to study the effect of HCV infection on IFN-induced expression of MHC class I genes, BioLegend LOC450151 antibody (BioLegend, W6/32) was used in western blot on human samples (fig 2). Gastroenterology (2014) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human
BioLegend LOC450151 antibody (Biolegend, 311403) was used in flow cytometry on human samples . PLoS ONE (2013) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 2d
In order to assess how different concentrations of IFN-gamma affect dendritic cells, BioLegend LOC450151 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig 2d). J Leukoc Biol (2014) ncbi
Articles Reviewed
  1. Heusinger E, Deppe K, Sette P, Krapp C, Kmiec D, Kluge S, et al. Preadaptation of Simian Immunodeficiency Virus SIVsmm Facilitated Env-Mediated Counteraction of Human Tetherin by Human Immunodeficiency Virus Type 2. J Virol. 2018;92: pubmed publisher
  2. Liu R, Merola J, Manes T, Qin L, Tietjen G, Lopez Giraldez F, et al. Interferon-γ converts human microvascular pericytes into negative regulators of alloimmunity through induction of indoleamine 2,3-dioxygenase 1. JCI Insight. 2018;3: pubmed publisher
  3. Jung Y, Cackowski F, Yumoto K, Decker A, Wang J, Kim J, et al. CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. Cancer Res. 2018;78:2026-2039 pubmed publisher
  4. Barkal A, Weiskopf K, Kao K, Gordon S, Rosental B, Yiu Y, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2018;19:76-84 pubmed publisher
  5. Mwimanzi F, Toyoda M, Mahiti M, Mann J, Martin J, Bangsberg D, et al. Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals. J Virol. 2018;92: pubmed publisher
  6. Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101-105 pubmed publisher
  7. Zhang X, Lian X, Dai Z, Zheng H, Chen X, Zheng Y. ?3-Deletion Isoform of HLA-A11 Modulates Cytotoxicity of NK Cells: Correlations with HIV-1 Infection of Cells. J Immunol. 2017;199:2030-2042 pubmed publisher
  8. Johnson D, Wayt J, Wilson J, Donaldson J. Arf6 and Rab22 mediate T cell conjugate formation by regulating clathrin-independent endosomal membrane trafficking. J Cell Sci. 2017;130:2405-2415 pubmed publisher
  9. Dever D, Bak R, Reinisch A, Camarena J, Washington G, Nicolas C, et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 2016;539:384-389 pubmed publisher
  10. Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, et al. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells. Proc Natl Acad Sci U S A. 2016;113:E6467-E6475 pubmed
  11. Tagawa T, Albanese M, Bouvet M, Moosmann A, Mautner J, Heissmeyer V, et al. Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing. J Exp Med. 2016;213:2065-80 pubmed publisher
  12. Sadallah S, Schmied L, Eken C, Charoudeh H, Amicarella F, Schifferli J. Platelet-Derived Ectosomes Reduce NK Cell Function. J Immunol. 2016;197:1663-71 pubmed publisher
  13. Liu C, LeClair P, Monajemi M, Sly L, Reid G, Lim C. α-Integrin expression and function modulates presentation of cell surface calreticulin. Cell Death Dis. 2016;7:e2268 pubmed publisher
  14. Reches A, Nachmani D, Berhani O, Duev Cohen A, Shreibman D, Ophir Y, et al. HNRNPR Regulates the Expression of Classical and Nonclassical MHC Class I Proteins. J Immunol. 2016;196:4967-76 pubmed publisher
  15. Li H, Borrego F, Nagata S, Tolnay M. Fc Receptor-like 5 Expression Distinguishes Two Distinct Subsets of Human Circulating Tissue-like Memory B Cells. J Immunol. 2016;196:4064-74 pubmed publisher
  16. Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Blagitko Dorfs N, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7:12840-56 pubmed publisher
  17. Johnson D, Estrada M, Salgado R, Sanchez V, Doxie D, Opalenik S, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582 pubmed publisher
  18. Thuring C, Follin E, Geironson L, Freyhult E, Junghans V, Harndahl M, et al. HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma. Br J Cancer. 2015;113:952-62 pubmed publisher
  19. Yawata N, Selva K, Liu Y, Tan K, Lee A, Siak J, et al. Dynamic change in natural killer cell type in the human ocular mucosa in situ as means of immune evasion by adenovirus infection. Mucosal Immunol. 2016;9:159-70 pubmed publisher
  20. Jørgensen M, Bæk R, Varming K. Potentials and capabilities of the Extracellular Vesicle (EV) Array. J Extracell Vesicles. 2015;4:26048 pubmed publisher
  21. Boerman G, van Ostaijen Ten Dam M, Kraal K, Santos S, Ball L, Lankester A, et al. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells. Cancer Immunol Immunother. 2015;64:573-83 pubmed publisher
  22. Bradley S, Chen Z, Melendez B, Talukder A, Khalili J, Rodríguez Cruz T, et al. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunol Res. 2015;3:602-9 pubmed publisher
  23. Nambiar J, Clarke A, Shim D, Mabon D, Tian C, Windloch K, et al. Potent neutralizing anti-CD1d antibody reduces lung cytokine release in primate asthma model. MAbs. 2015;7:638-50 pubmed publisher
  24. Tomimaru Y, Mishra S, Safran H, Charpentier K, Martin W, De Groot A, et al. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma. Vaccine. 2015;33:1256-66 pubmed publisher
  25. Boltjes A, van Montfoort N, Biesta P, Op den Brouw M, Kwekkeboom J, van der Laan L, et al. Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function. J Infect Dis. 2015;211:1268-78 pubmed publisher
  26. Matheson N, Peden A, Lehner P. Antibody-free magnetic cell sorting of genetically modified primary human CD4+ T cells by one-step streptavidin affinity purification. PLoS ONE. 2014;9:e111437 pubmed publisher
  27. Chao Y, Kaliaperumal N, Chretien A, Tang S, Lee B, Poidinger M, et al. Human plasmacytoid dendritic cells regulate IFN-α production through activation-induced splicing of IL-18Rα. J Leukoc Biol. 2014;96:1037-46 pubmed publisher
  28. Davey M, Morgan M, Liuzzi A, Tyler C, Khan M, Szakmany T, et al. Microbe-specific unconventional T cells induce human neutrophil differentiation into antigen cross-presenting cells. J Immunol. 2014;193:3704-3716 pubmed publisher
  29. Jung Y, Wang J, Lee E, McGee S, Berry J, Yumoto K, et al. Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. Mol Cancer Res. 2015;13:197-207 pubmed publisher
  30. Vogel K, Thomann S, Vogel B, Schuster P, Schmidt B. Both plasmacytoid dendritic cells and monocytes stimulate natural killer cells early during human herpes simplex virus type 1 infections. Immunology. 2014;143:588-600 pubmed publisher
  31. Noviello M, Tedesco F, Bondanza A, Tonlorenzi R, Rosaria Carbone M, Gerli M, et al. Inflammation converts human mesoangioblasts into targets of alloreactive immune responses: implications for allogeneic cell therapy of DMD. Mol Ther. 2014;22:1342-1352 pubmed publisher
  32. Kang W, Sung P, Park S, Yoon S, Chang D, Kim S, et al. Hepatitis C virus attenuates interferon-induced major histocompatibility complex class I expression and decreases CD8+ T cell effector functions. Gastroenterology. 2014;146:1351-60.e1-4 pubmed publisher
  33. Fuentes T, Appleby N, Tsay E, Martinez J, Bailey L, Hasaniya N, et al. Human neonatal cardiovascular progenitors: unlocking the secret to regenerative ability. PLoS ONE. 2013;8:e77464 pubmed publisher
  34. Svajger U, Obermajer N, Jeras M. IFN-?-rich environment programs dendritic cells toward silencing of cytotoxic immune responses. J Leukoc Biol. 2014;95:33-46 pubmed publisher